{"groups":[{"description":"4mg by IV over 15 minutes every 4 weeks in the absence of disease progression or the first skeletal-related event. Participants who progression on blinded treatment before having a skeletal event may continue on open label Zoledronic acid (4 mg by IV over 15 minutes every 3 weeks).","id":"FG000","title":"Zoledronic Acid + Androgen Deprivation Therapy"},{"description":"Placebo bu IV over 15 minutes for 4 weeks in the absence of disease progression or the first skeletal-related event. Participants who progress on blinded treatment before having a skeletal event may continue on open label Zoledronic acid.","id":"FG001","title":"Placebo + Androgen Deprivation Therapy"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"323"},{"groupId":"FG001","numSubjects":"322"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"323"},{"groupId":"FG001","numSubjects":"322"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Between January 2004 and May 2012, 645 participants were registered and randomized."}